About Paradigm

Our mission is to create equitable access to clinical trials for any patient, anywhere

 


Paradigm is rebuilding the clinical research ecosystem by creating a platform that enables equitable access to trials for all patients, while enhancing trial efficiency and reducing the barriers to participation for healthcare providers. Incubated by ARCH Venture Partners and backed by leading healthcare and life sciences investors, Paradigm aims to break down barriers across the trial ecosystem through one seamless infrastructure implemented at healthcare provider organizations, bringing potentially life-saving therapies to patients faster.

Learn more about Paradigm’s impact to reduce clinical trial burden and expand patient access to the best possible care.

Leadership


Kent Thoelke - bw


Kent Thoelke
Chief Executive Officer

Jonathan Hirsch bw


Jonathan Hirsch
Chief Strategy & Growth Officer

Jay Trepanier bw


Jay Trepanier
Chief Financial Officer

 

Elijah Meerson bw


Elijah Meerson
Chief Technology Officer

Michelle Lee


Michelle Lee
Chief Operating Officer

 

 

Board of Directors



Robert Nelsen
Co-founder and Managing Director, ARCH Venture Partners


Hemant Taneja
CEO and Managing Director, General Catalyst


Stephen Knight, MD
President and Managing Partner, F-Prime

 


Kenneth C. Frazier
Former Executive Chairman & CEO, Merck


General (Ret) Gustave F. Perna
Former COO, Operation Warp Speed
 


Stephen Klasko, MD MBA
Former CEO, Jefferson Health
 

 


Luciana Borio, MD
Former Chief Scientist, U.S. Food & Drug Administration


Elena Viboch
Partner, General Catalyst
 

Kent Thoelke - bw


Kent Thoelke
Chief Executive Officer, Paradigm

Investors


 

General Catalyst Logo Black and Purple

 

FPrime black

 

Lux Capital

 

Mubadala Capital

 

gv_transparent

 

Magnetic Ventures Logo

 

American Cancer Society BrightEdge

 

Connect with Us


Stay up to date with the latest Paradigm news, updates and information.